Regulatory approval

Published by the Health Service Executive. Approved

The Republic of Ireland's Health Service Executive (HSE) has approved brentuximab vedotin in combination with ICE (etoposide, carboplatin, and ifosfamide) for reimbursement as a treatment option for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin's lymphoma (HL).

This is written in the approval document as:

Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL)

Reimbursement

Incomplete Reimbursement

Brentuximab - ODMS; Carboplatin, Etoposide, Ifosfamide - N/A

Citation

Brentuximab vedotin and ICE Therapy, 2024, version number 2, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6525/528_v2_B_ICE.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	CD30 +	Hodgkin Lymphoma	Brentuximab vedotin, Carboplatin, Etoposide, Ifosfamide

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2021-11-12	Health Service Executive	Indication approved for reimbursement.